List view / Grid view




Medimmune and Inovio Pharmaceuticals agree to DNA-based immunotherapy collaboration

11 August 2015 | By Katie Sadler, Digital Content Producer, European Pharmaceutical Review

AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a license agreement and collaboration with Inovio Pharmaceuticals, a biotechnology company developing DNA-based immunotherapies for cancer and infectious diseases.